Coya Therapeutics Enters Material Definitive Agreement
Ticker: COYA · Form: 8-K · Filed: Jun 5, 2024 · CIK: 1835022
| Field | Detail |
|---|---|
| Company | Coya Therapeutics, Inc. (COYA) |
| Form Type | 8-K |
| Filed Date | Jun 5, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001, $3.85 million, $6 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-definitive-agreement
TL;DR
Coya Therapeutics just signed a big deal, details TBD.
AI Summary
Coya Therapeutics, Inc. announced on June 4, 2024, that it entered into a Material Definitive Agreement. The filing does not disclose the specific details of this agreement or any associated financial figures.
Why It Matters
This filing indicates a significant new development for Coya Therapeutics, potentially impacting its business operations and future strategy.
Risk Assessment
Risk Level: medium — The lack of specific details in the filing regarding the material definitive agreement introduces uncertainty about its nature and potential impact.
Key Players & Entities
- Coya Therapeutics, Inc. (company) — Registrant
- June 4, 2024 (date) — Date of earliest event reported
FAQ
What is the nature of the Material Definitive Agreement entered into by Coya Therapeutics?
The filing does not specify the details of the Material Definitive Agreement.
When did Coya Therapeutics enter into this Material Definitive Agreement?
The earliest event reported in the filing is June 4, 2024.
Does the filing disclose any financial terms or dollar amounts related to the agreement?
No, the filing does not disclose any specific financial terms or dollar amounts related to the agreement.
What is the principal executive office address for Coya Therapeutics?
The address of the principal executive offices is 5850 San Felipe St., Suite 500, Houston, Texas 77057.
What is the SIC code for Coya Therapeutics?
The Standard Industrial Classification (SIC) code for Coya Therapeutics is 2834, Pharmaceutical Preparations.
Filing Stats: 581 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2024-06-05 08:00:32
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share COYA The Nasdaq Stock Mar
- $3.85 million — ke a one-time payment to the Company of $3.85 million to be used solely for the purposes of f
- $6 million — obligation to pay the Company the first $6 million in royalty payments that otherwise woul
Filing Documents
- d838051d8k.htm (8-K) — 24KB
- d838051dex101.htm (EX-10.1) — 9KB
- 0001193125-24-154729.txt ( ) — 159KB
- coya-20240604.xsd (EX-101.SCH) — 3KB
- coya-20240604_lab.xml (EX-101.LAB) — 18KB
- coya-20240604_pre.xml (EX-101.PRE) — 11KB
- d838051d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. COYA THERAPEUTICS, INC. Date:June 5, 2024 By: /s/ Howard Berman Howard Berman Chief Executive Officer